Immuneering (IMRX) Operating Expenses (2020 - 2026)
Immuneering (IMRX) posted quarterly Operating Expenses of $15.3 million for Q1 2026, down 0.97% year-over-year from $15.5 million in Q1 2025, and up 11.51% quarter-over-quarter from $13.8 million in Q4 2025.
Immuneering (IMRX) Operating Expenses (2020 - 2026) Analysis & Trends
Immuneering's Operating Expenses history runs 7 years deep, the most recent figure standing at $15.3 million for Q1 2026.
- In Q1 2026, Operating Expenses fell 0.97% year-over-year to $15.3 million; the TTM figure through Mar 2026 stood at $59.2 million (down 7.79% YoY), while the FY2025 annual figure was $59.4 million, down 7.33% from the prior year.
- Operating Expenses for Q1 2026 stood at $15.3 million, up from $13.8 million in the prior quarter.
- The five-year high for Operating Expenses was $18.6 million in Q4 2024, with the low at $11.7 million in Q2 2022.
- The 5-year median for Operating Expenses is $14.8 million (2025), against an average of $14.7 million.
- The sharpest annual moves came in 2022 and 2025: Operating Expenses jumped 98.0% in 2022, then declined 25.89% in 2025.
- Immuneering's Operating Expenses stood at $14.0 million in 2022, then increased by 16.56% to $16.3 million in 2023, then climbed by 13.84% to $18.6 million in 2024, then declined by 25.89% to $13.8 million in 2025, then rose by 11.51% to $15.3 million in 2026.
- Business Quant data shows IMRX's Operating Expenses at $15.3 million in Q1 2026, $13.8 million in Q4 2025, and $15.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | 19.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.00 Mn |
| Mar 31, 2026 | 15.34 Mn |
| Dec 31, 2025 | 13.75 Mn |
| Sep 30, 2025 | 15.38 Mn |
| Jun 30, 2025 | 14.76 Mn |
| Mar 31, 2025 | 15.48 Mn |
| Dec 31, 2024 | 18.56 Mn |
| Sep 30, 2024 | 15.27 Mn |
| Jun 30, 2024 | 14.91 Mn |
| Mar 31, 2024 | 15.33 Mn |
| Dec 31, 2023 | 16.30 Mn |
| Sep 30, 2023 | 13.93 Mn |
| Jun 30, 2023 | 13.50 Mn |
| Mar 31, 2023 | 14.68 Mn |
| Dec 31, 2022 | 13.99 Mn |
| Sep 30, 2022 | 13.21 Mn |
| Jun 30, 2022 | 11.69 Mn |
| Mar 31, 2022 | 13.02 Mn |
| Dec 31, 2021 | 11.10 Mn |
| Sep 30, 2021 | 8.81 Mn |